

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified human or humanized IgG<sub>3</sub> monoclonal antibody which specifically binds *Staphylococcus aureus* protein A (SpA) with a K<sub>D</sub> of less than 1 x 10<sup>-10</sup> M via its Fab region paratope and has an Fc region able to interact with an FcR when the antibody is bound to SpA by its Fab region paratope, wherein the monoclonal antibody is (i) able to displace human IgG immunoglobulins bound to SpA on *Staphylococcus aureus* bacteria via their Fc regions and (ii) able to treat a *Staphylococcus aureus* infection in a subject when administered to the subject.

2. The pharmaceutical composition of claim 1, wherein the monoclonal antibody comprises:

(i) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 12, 13, and 14, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 17, 18, and 19, respectively;

(ii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 22, 23, and 24, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 27, 28, and 29, respectively;

(iii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 32, 33, and 34, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 37, 38, and 39, respectively;

(iv) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 42, 43, and 44, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 47, 48, and 49, respectively;

(v) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 52, 53, and 54, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 57, 58, and 59, respectively;

(vi) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 62, 63, and 64, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 67, 68, and 69, respectively; or

(vii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 72, 73, and 74, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 77, 78, and 79, respectively.

3. The pharmaceutical composition of claim 1, wherein the antibody comprises a variable domain selected from the group of:

- (i) SEQ ID NO: 5;
- (ii) SEQ ID NO: 10;
- (iii) SEQ ID NO: 15;
- (iv) SEQ ID NO: 20;
- (v) SEQ ID NO: 25;
- (vi) SEQ ID NO: 30;
- (vii) SEQ ID NO: 35;
- (viii) SEQ ID NO: 40;
- (ix) SEQ ID NO: 45;
- (x) SEQ ID NO: 50;
- (xi) SEQ ID NO: 55;
- (xii) SEQ ID NO: 60;
- (xiii) SEQ ID NO: 65;
- (xiv) SEQ ID NO: 70;
- (xv) SEQ ID NO: 75; or
- (xvi) SEQ ID NO: 80.

4. The pharmaceutical composition of claim 1, wherein the monoclonal antibody binds SpA with a  $K_D$  of less than  $1 \times 10^{-12}$  M via its Fab region paratope.